Sanofi: Ovarian Neoplasms trials
The registry lists 14 Ovarian Neoplasms studies with Sanofi as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 3Phase 2 11Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD)TerminatedNCT00862836Phase 1/2Results posted
- AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant AscitesCompletedNCT00396591Phase 2Results posted
- Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant AscitesCompletedNCT00327444Phase 2/3Results posted
- Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian CancerCompletedNCT00327171Phase 2Results posted
- TEACO: Taxotere, Eloxatin, Avastin in Cancer of the OvaryCompletedNCT00296816Phase 2Results posted
- (VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1
- Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/PaclitaxelCompletedNCT01332656Phase 2
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian CancerCompletedNCT01033292Phase 2
- A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian CancerCompletedNCT01033123Phase 2
- Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian CancerCompletedNCT00772863Phase 2
- Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsCompletedNCT00756847Phase 1
- TAX + Carboplatin or Cisplatin 1st Line Post-Surgery OvarianCompletedNCT00539669Phase 2
- Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian CancerCompletedNCT00452985
- ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous TreatmentWithdrawnNCT00005645Phase 2